List of Excipients in Branded Drug ZYRTEC-D

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Kenvue Brands LLC	ZYRTEC-D	cetirizine hydrochloride and pseudoephedrine hydrochloride	50580-719	CELLULOSE, MICROCRYSTALLINE
Kenvue Brands LLC	ZYRTEC-D	cetirizine hydrochloride and pseudoephedrine hydrochloride	50580-719	CROSCARMELLOSE SODIUM
Kenvue Brands LLC	ZYRTEC-D	cetirizine hydrochloride and pseudoephedrine hydrochloride	50580-719	HYPROMELLOSE
Kenvue Brands LLC	ZYRTEC-D	cetirizine hydrochloride and pseudoephedrine hydrochloride	50580-719	LACTOSE MONOHYDRATE
Kenvue Brands LLC	ZYRTEC-D	cetirizine hydrochloride and pseudoephedrine hydrochloride	50580-719	MAGNESIUM STEARATE
Kenvue Brands LLC	ZYRTEC-D	cetirizine hydrochloride and pseudoephedrine hydrochloride	50580-719	POLYETHYLENE GLYCOL
Kenvue Brands LLC	ZYRTEC-D	cetirizine hydrochloride and pseudoephedrine hydrochloride	50580-719	SILICON DIOXIDE

Zyrtec-D Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Zyrtec-D is an extended-release combination tablet containing cetirizine hydrochloride 5 mg and pseudoephedrine hydrochloride 120 mg. The commercial opportunity is primarily in generic and private-label substitution, formulation-cost reduction, supply-chain resilience, and improved extended-release performance. The product is an OTC combination rather than a biologic, so biosimilar risk is irrelevant. The principal technical barrier is maintaining pseudoephedrine release over 12 hours while preserving cetirizine release, tablet integrity, and bioequivalence.

The strongest excipient opportunity is a robust, low-cost hydrophilic or hybrid matrix that controls pseudoephedrine release across manufacturing and physiological conditions. A secondary opportunity is an abuse-resistant or tamper-resistant platform that limits rapid extraction or dose dumping without materially increasing tablet cost.

What is Zyrtec-D and which dosage form creates the formulation opportunity?

Zyrtec-D 12 Hour is an oral, multilayer or matrix-controlled extended-release tablet containing:

Attribute	Product profile
Active ingredients	Cetirizine hydrochloride and pseudoephedrine hydrochloride
Strength	5 mg cetirizine HCl / 120 mg pseudoephedrine HCl
Administration	One tablet every 12 hours
Dosage form	Extended-release oral tablet
Therapeutic use	Allergic rhinitis with nasal congestion
Regulatory category	OTC combination product marketed under FDA requirements
Controlled substance status	Pseudoephedrine is subject to federal retail-sale and purchase restrictions
Biosimilar relevance	None
Primary formulation challenge	Controlled delivery of a high-dose, water-soluble decongestant

Pseudoephedrine represents most of the tablet's active mass. It is highly water soluble, which creates a substantial risk of rapid release if the matrix is undercontrolled, porous, damaged, or sensitive to alcohol and food conditions. Cetirizine is present at a much lower dose and generally imposes less mass-balance pressure on the extended-release system.

What excipients are used or commercially relevant in Zyrtec-D?

Public product labeling identifies inactive ingredients for the marketed product, but commercial formulations can change by manufacturer, site, or approved supplement. Exact excipient composition should therefore be evaluated against the current product label and the relevant FDA submission.

The most commercially relevant excipient classes are:

Excipient class	Technical role	Zyrtec-D opportunity
Hypromellose	Hydrophilic gel-forming matrix and release controller	Main platform for 12-hour pseudoephedrine release
Microcrystalline cellulose	Filler, compression aid, structural diluent	Supports direct compression and tablet robustness
Lactose or alternative filler	Mass adjustment and compression	Opportunity for lactose-free or low-cost reformulation
Croscarmellose sodium	Disintegrant	Must be controlled to prevent premature matrix disruption
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves flow of high-dose powder blends
Magnesium stearate	Lubricant	Excess use can slow wetting and impair dissolution
Hypromellose or film-coating polymers	Film formation, appearance, protection	Can improve handling and reduce friability
Polyethylene glycol and pigments	Coating and identification	Limited performance value but relevant to manufacturing
Ethylcellulose or other insoluble polymers	Barrier or release-control component	Useful in hybrid matrix or multiparticulate designs
Povidone or copovidone	Binder and granulation aid	May improve tablet strength and content uniformity

The commercial formulation should minimize excipient count where possible. Each additional excipient increases supplier qualification, analytical testing, regulatory documentation, and potential variability in dissolution.

How should an excipient strategy control pseudoephedrine release?

A hydrophilic matrix is the most practical starting point. Hypromellose hydrates after administration, forms a gel layer, and controls water penetration and drug diffusion. The formulation variables with the greatest impact are polymer viscosity grade, polymer concentration, particle size, compression force, tablet porosity, lubricant level, and granulation method.

A development program should compare three platforms:

Hydrophilic matrix

A hypromellose matrix is likely to offer the lowest manufacturing complexity. It can be produced by direct compression or wet granulation and is compatible with conventional tablet equipment.

Key advantages include:

• Low excipient cost.
• Straightforward scale-up.
• Broad supplier availability.
• Compatibility with generic development.
• Established regulatory precedent.

The main risk is sensitivity to compression and excipient lot variation. Higher compression can reduce porosity and slow release. Excessive lubrication can delay hydration and change the dissolution profile.

Hybrid hydrophilic-insoluble matrix

Combining hypromellose with ethylcellulose or another water-insoluble polymer can reduce burst release and improve robustness. The approach may be useful when the high pseudoephedrine load causes excessive initial dissolution.

The cost is greater process complexity and a higher risk that the formulation will require extensive comparative dissolution work. A hybrid matrix can also make bioequivalence more difficult if the release mechanism differs materially from the reference product.

Coated particles or multiparticulates

Pseudoephedrine can be incorporated into coated granules or multiparticulates before compression. This creates greater control over release and can reduce the effect of tablet damage.

The platform is technically stronger but commercially less attractive for a standard generic because it can require:

• Specialized coating equipment.
• More complex in-process controls.
• Higher batch costs.
• More difficult scale-up.
• Increased risk of manufacturing deviations.

Multiparticulates become more attractive for line extensions, abuse-deterrent products, or formulations designed to reduce alcohol-induced dose dumping.

What excipient innovations could create commercial differentiation?

The most practical opportunities are performance-led rather than ingredient-led. A new excipient has limited value unless it produces a measurable improvement in dissolution robustness, manufacturability, stability, or cost.

Low-swell, high-viscosity matrices

A polymer that provides strong gel strength at lower use levels could reduce tablet size and improve pseudoephedrine release control. This is commercially relevant because Zyrtec-D has a high active load and must remain swallowable.

Direct-compression platforms

A co-processed filler-binder, such as a cellulose-based or silicified material, could reduce wet granulation, drying, and process time. The development target is a blend with:

• High flow.
• Low segregation risk.
• Adequate tablet hardness.
• Low friability.
• Stable dissolution after storage.
• Low sensitivity to lubricant concentration.

Moisture-managed excipient systems

Moisture can alter powder flow, tablet hardness, polymer hydration, and dissolution. A low-moisture excipient system could improve stability in humid markets and reduce packaging requirements. Desiccant packaging remains a lower-risk option than adding a specialized moisture-scavenging excipient.

Alcohol-resistant release systems

Extended-release pseudoephedrine products face concern over rapid release in the presence of alcohol. A matrix or coating system that maintains release in hydroalcoholic media could provide a regulatory and product-quality advantage. Any such claim would require a defined testing strategy and alignment with FDA expectations for modified-release products.

Lactose-free and allergen-positioned formulations

A lactose-free formulation may appeal to private-label customers and consumers who avoid lactose. The commercial value is moderate because lactose excipients are inexpensive and many consumers do not require avoidance. The formulation must preserve compression, dissolution, and stability after substituting microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler.

Lower-tablet-weight formulations

Reducing total tablet mass could improve patient acceptability. The opportunity is constrained by the 120 mg pseudoephedrine dose and the amount of polymer needed for 12-hour release. High-density fillers and efficient polymer systems provide the most credible route.

What patents protect Zyrtec-D and when does the product lose exclusivity?

The active ingredients are long-established. Cetirizine and pseudoephedrine do not provide a meaningful new-molecule exclusivity barrier for current competition. Historical patents associated with cetirizine, pseudoephedrine, and earlier Zyrtec products have expired or are unlikely to block ordinary generic development.

The relevant protection categories are:

Protection category	Commercial relevance
Cetirizine compound patents	Historical protection; expired
Pseudoephedrine compound patents	Historical protection; expired
Combination patents	Potentially relevant only if an unexpired claim covers the specific combination or dosage regimen
Extended-release formulation patents	Main possible barrier for a differentiated product
Method-of-use patents	Potentially relevant to allergic rhinitis or congestion claims, but generally weak against OTC substitution unless enforceable and listed
Manufacturing patents	Could affect a specific process, but usually avoidable through alternative manufacturing routes
Trademark and trade dress	Relevant to branding, not generic technical entry

No current patent should be assumed to block a 5 mg/120 mg generic without a claim-by-claim review of active U.S. patents, FDA Orange Book listings, and litigation records. Patent risk is most likely to arise from a later formulation patent rather than from the basic active ingredients.

What is the Orange Book status of Zyrtec-D?

The Orange Book is most relevant to FDA-approved drug products and listed patents. Zyrtec-D is an OTC combination product, and its regulatory treatment does not create the same patent-certification profile as a conventional prescription product.

A prospective manufacturer should distinguish among:

1. An OTC product marketed under an applicable monograph pathway.
2. An OTC product supported by an FDA-approved application.
3. A private-label product relying on an approved reference product or other permitted regulatory route.
4. A product requiring an ANDA, NDA, or supplemental application because of formulation, dosage-form, or labeling differences.

The presence or absence of an Orange Book-listed patent does not eliminate technical or regulatory risk. A formulation change can trigger a different FDA pathway even when the active ingredients are old.

Are Paragraph IV challenges, litigation, or settlements material?

Paragraph IV risk is not expected to be the central commercial issue for a standard Zyrtec-D generic unless an applicable approved reference product has active listed patents. The more immediate risks are:

• Whether the proposed product qualifies for the intended OTC or ANDA pathway.
• Whether the dissolution profile matches the reference.
• Whether the formulation shows dose dumping under hydroalcoholic conditions.
• Whether labeling and pseudoephedrine controls are compliant.
• Whether the product creates a new patent claim through its own excipient system.

No major current settlement structure should be presumed to govern ordinary Zyrtec-D entry. A launch assessment should separately search federal district court records, the FDA Orange Book, FDA product-specific guidance, and patent assignment databases.

What is the FDA regulatory status of Zyrtec-D?

Zyrtec-D combines an antihistamine with an oral nasal decongestant. Cetirizine is addressed within FDA's OTC antihistamine framework, while pseudoephedrine is subject to OTC nasal-decongestant requirements and federal retail controls. The combination must satisfy applicable labeling, dosage, warning, and performance requirements.

Pseudoephedrine creates operational obligations under the Combat Methamphetamine Epidemic Act, including sales limits, purchaser identification, logbook requirements, and storage controls for nonprescription products (U.S. Congress, 2005).

An excipient strategy must account for:

• FDA inactive-ingredient acceptability.
• Daily exposure from the 12-hour dosage regimen.
• Food-effect and alcohol-effect testing.
• Stability under commercial packaging.
• Dissolution similarity to the reference product.
• Labeling for sedation, hypertension, insomnia, and contraindicated use.
• Retail controls associated with pseudoephedrine.

What generic launch risks exist for Zyrtec-D?

The most credible launch scenarios are:

Launch scenario	Probability profile	Main risk
Standard hydrophilic-matrix generic	Highest practicality	Dissolution and bioequivalence
Private-label version using the same technical platform	High commercial potential	Retail distribution and pseudoephedrine controls
Lactose-free or low-excipient version	Moderate	Limited consumer willingness to pay
Abuse-resistant or alcohol-resistant version	Moderate but technically demanding	Cost and regulatory substantiation
Novel multiparticulate product	Lower for basic generic entry	Manufacturing complexity
Liquid or chewable extension	Lower	Different stability, taste, and regulatory requirements

The principal commercial threat is price erosion. A basic generic tablet has limited defensibility because the active ingredients are mature and the excipient technology is broadly available. Differentiation requires either a lower cost of goods, a reliable supply advantage, an improved patient attribute, or a defensible formulation patent.

How does Zyrtec-D compare with competing allergy products?

Zyrtec-D competes against pseudoephedrine combinations containing loratadine or other antihistamines, as well as separate antihistamine and decongestant products.

Product type	Main advantage	Excipient opportunity
Cetirizine/pseudoephedrine ER	Familiar antihistamine plus congestion relief	Matrix robustness and lower tablet burden
Loratadine/pseudoephedrine ER	Different sedation and tolerability profile	Comparable release-control opportunity
Cetirizine immediate release plus separate pseudoephedrine	Flexible dosing	Lower convenience and adherence
Intranasal steroid plus oral antihistamine	Strong local nasal therapy	Different dosage form and device economics
Phenylephrine combinations	Broad retail availability	Weaker decongestant efficacy concerns create positioning risk

Zyrtec-D's formulation value is concentrated in the 12-hour delivery system. The active-ingredient combination itself is not a strong source of exclusivity.

How strong is the Zyrtec-D patent estate?

The estate is weak for the core active ingredients and potentially moderate for a narrowly drafted improved-release formulation. A new entrant should rank risks as follows:

1. Reference-product formulation and dissolution requirements.
2. FDA pathway and bioequivalence.
3. Manufacturing reproducibility.
4. Pseudoephedrine retail compliance.
5. Unexpired formulation or process claims.
6. Trademark and trade-dress constraints.

A formulation patent could be commercially meaningful if it claims a specific polymer ratio, release profile, hydroalcoholic performance, or multilayer structure. Broad claims covering ordinary hypromellose matrices are more vulnerable to validity and design-around challenges.

Key Takeaways

• Zyrtec-D contains cetirizine hydrochloride 5 mg and pseudoephedrine hydrochloride 120 mg in a 12-hour extended-release tablet.
• The main excipient opportunity is a robust matrix that controls the high-dose, highly soluble pseudoephedrine component.
• Hypromellose-based systems offer the best balance of cost, regulatory familiarity, and manufacturing simplicity.
• Hybrid matrices, coated particles, and alcohol-resistant technologies offer greater differentiation but increase development cost.
• Historical active-ingredient patents do not provide a meaningful current barrier to ordinary generic entry.
• Orange Book, FDA pathway, and product-specific patent status must be reviewed before selecting an ANDA, NDA, or OTC strategy.
• Pseudoephedrine retail controls are a material commercial and operational constraint.
• The strongest business cases are low-cost generic supply, private-label distribution, lactose-free positioning, and technically differentiated release performance.
• Biosimilar competition does not apply because Zyrtec-D is a small-molecule oral product.

FAQs

Can hypromellose be used in a generic Zyrtec-D formulation?

Yes. Hypromellose is a conventional extended-release matrix former. Polymer grade, concentration, compression, and dissolution performance must be optimized against the reference product.

Is a Zyrtec-D generic required to use the same excipients as the reference product?

No. A generic may use different inactive ingredients if the formulation meets FDA requirements, remains pharmaceutically acceptable, and demonstrates the required quality and bioequivalence.

Does pseudoephedrine make Zyrtec-D a controlled substance?

Pseudoephedrine is not generally scheduled as a controlled substance, but federal law imposes quantity limits, purchaser identification, recordkeeping, and retail-storage requirements.

Can an excipient formulation create new patent protection for Zyrtec-D?

Yes. A novel release system, hydroalcoholic-resistant matrix, multilayer tablet, or manufacturing process may support patent claims if it satisfies novelty, nonobviousness, and written-description requirements.

Is a biosimilar filing possible for Zyrtec-D?

No. Biosimilar applications apply to biological products. Zyrtec-D is a small-molecule combination tablet and would use an applicable generic, OTC, or NDA-based pathway.

References

1. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. U.S. Government Publishing Office.

2. U.S. Congress. (2005). Combat Methamphetamine Epidemic Act of 2005, Pub. L. No. 109-177, Title VII.

3. U.S. Food and Drug Administration. (2018). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2023). Inactive ingredient database. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

6. U.S. National Library of Medicine. (2024). DailyMed: Cetirizine hydrochloride and pseudoephedrine hydrochloride extended-release tablet labeling. National Institutes of Health.